Oragenics raises $16.5M, advances ONP-002 Phase IIa concussion trial for Q3 2025

ORAGENICS INC

Raised $16.5M via Series H Preferred Stock and Warrants; net proceeds ~$15.2M after fees.
HREC approval secured in Australia; Southern Star Research appointed CRO; Sterling Pharma Solutions for cGMP manufacturing.
Phase IIa trial initiation anticipated Q3 2025; IND submission for Phase IIb expected Q3-Q4 2025.
Six months ended June 30, 2025: R&D expenses down 50%, G&A costs down 8%, net losses down 6% YoY.
No FDA-approved pharmacological treatment currently exists for concussion; market opportunity $8.9B by 2027.

item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001641172-25-022908
form_type: 8-K
ticker: OGEN
cik: 0001174940
company_name: ORAGENICS INC
filed_at: 2025-08-11T23:59:59+00:00
discovered_at: 2026-05-14T18:02:43.489398+00:00
generated_at: 2026-05-17T15:12:02.135108+00:00
sec_items: ["8.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.6
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001641172-25-022908
json_url: https://secwatch.observer/filing/0001641172-25-022908.json
markdown_url: https://secwatch.observer/filing/0001641172-25-022908.md
text_url: https://secwatch.observer/filing/0001641172-25-022908.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1174940/000164117225022908/0001641172-25-022908-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1174940/000164117225022908/form8-k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001641172-25-022908

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.